By Canadian Press

saving for second doses

Alberta to stop giving first doses of AstraZeneca COVID-19 shot as supply dwindles

May 11, 2021 | 9:07 AM

OTTAWA — Alberta says it won’t give out more first doses of the Oxford-AstraZeneca vaccine for the time being.

A spokesman for the provincial health department says the decision was made because there aren’t any confirmed shipments of AstraZeneca coming, and the province only has 8,400 doses of it left.

As such, they will save what they have for second doses.

“Unlike with AstraZeneca, Alberta is receiving the Pfizer and Moderna vaccines in large and consistent shipments,” said Alberta Health assistant communications director Tom McMillan.

“More than 236,000 doses are arriving this week alone.”

Riderville

Shades of 2007

7h ago

Inflation

Rent inflation to slow in the next few years, Desjardins predicts

Nov 14, 2024

Election

Hawtin elected mayor in North Battleford; Battleford, Meadow Lake await results

Nov 14, 2024

Alberta appears to be the first province to officially take AstraZeneca out of the offerings for first doses but it likely won’t be the last. There are ongoing safety concerns for AstraZeneca but the decision is coming largely due to the practical realities of supply.

More than 18 million doses of Pfizer-BioNTech are expected between now and the end of June, and somewhere between eight and 10 million doses of Moderna. Another 15 million doses of Pifzer and between 26 million and 28 million doses of Moderna will be shipped by the end of September.

Comparatively, Canada expects 1.65 million doses of AstraZeneca by June 30, and about 20 million more AstraZeneca by the end of September.

Pfizer and Moderna are sending more than enough to vaccinate every Canadian with two doses.

Many provinces, including Ontario, are eagerly awaiting results of a clinical trial in the United Kingdom looking at giving a different vaccine for the second dose. That would allow people who got AstraZeneca first to be given Pfizer or Moderna for their second dose.

The first results looking at combining AstraZeneca and Pfizer could come this week and most health experts say the combination of vaccines may create an even better immune response.

AstraZeneca is potentially linked to a new blood clotting syndrome known as vaccine-induced thrombotic thrombocytopenia or VITT. The syndrome is extremely rare but can be fatal, and the real risk is still being determined.

The Ontario Science Table said Monday the reported incidents globally are between one in 26,000 and one in 127,000.

In Canada, at least 12 cases have been confirmed out of more than two million doses given. Three women have died.

The National Advisory Committee on Immunization says people at low risk of COVID-19 should wait until they can get a dose from Pfizer-BioNTech or Moderna.

Dr. Andrew Morris, an infectious diseases physician and director of the antimicrobial stewardship program at Sinai Health in Toronto, said given what we now know of the risk of VITT combined with greater supply of Pfizer and Moderna, and lower incidence of COVID-19 in most of Canada, the benefits of the AstraZeneca vaccine no longer outweigh the risks in most of Canada.

He said if COVID-19 hot spots in places like Toronto, Brampton, Winnipeg, and much of Alberta can’t get enough doses of Pfizer or Moderna, then AstraZeneca still is a good choice there.

“Everywhere else, it no longer makes sense based on what we know, to give AZ vaccine,” he said on Twitter.

This report by The Canadian Press was first published May 11, 2021.

Mia Rabson, The Canadian Press